BH-501284

BH-501284 is a small molecule (oral, non-covalent) from BlossomHill Therapeutics. An orally available pan-KRAS inhibitor on a non-covalent Switch-II scaffold, designed for prolonged, selective inhibition of mutant KRAS while sparing HRAS and NRAS. Its furthest stage is preclinical development, for solid tumours (KRAS-mutant). No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline shows IND-enabling. It has not been shown to work in people.